A
4.95
0.13 (2.70%)
| Previous Close | 4.82 |
| Open | 4.83 |
| Volume | 2,437,323 |
| Avg. Volume (3M) | 2,928,743 |
| Market Cap | 3,095,056,640 |
| Price / Sales | 5.42 |
| Price / Book | 1.21 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2024 |
| Profit Margin | -3.26% |
| Operating Margin (TTM) | 48.65% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | 2,509.00% |
| Total Debt/Equity (MRQ) | 1.44% |
| Current Ratio (MRQ) | 21.75 |
| Operating Cash Flow (TTM) | -55.49 M |
| Levered Free Cash Flow (TTM) | -1.78 B |
| Return on Assets (TTM) | -1.03% |
| Return on Equity (TTM) | -0.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ABBISKO-B | - | - |
AIStockmoo Score
0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ABBISKO-B | 3 B | - | - | 1.21 |
| LEPU BIO-B | 5 B | - | - | 4.75 |
| FRONTAGE | 3 B | - | 83.00 | 1.29 |
| ALPHAMAB-B | 3 B | - | - | 1.88 |
| CSTONE PHARMA-B | 3 B | - | - | 5.94 |
| GENOR-B | 930 M | - | - | 0.800 |
|
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 20.39% |
| % Held by Institutions | 23.85% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |